id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
eyereports-54	Palmowski-Wolfe, Anja M.; Pape, Eva; Baumann, Thomas; Todorova, Margarita G.	Idiopathic intracranial hypertension: a possible association with Imatinib	2011	3	.pdf	application/pdf	1763	99	55	This process can be blocked with imatinib which results in a reduction of the number of pathologic tumor cells.1 Meanwhile imatinib is also applied to treat patients with gastrointesti- nal stromal tumors.1 Imatinib is the only FDA approved tyrosine kinase inhibitor for the treat- ment of patients with systemic mastocytosis, where a majority of patients excessively express the mast and stem cell growth factor receptor, SCFR or CD117, encoded by the KIT gene, and which has tyrosine kinase activity.2 As imatinib has only been on the market for a relatively short time, with time, new side effects are being described.1 We report a possible association between imatinib and Idiopathic intracranial hypertension (IIH). Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.	cache/eyereports-54.pdf	txt/eyereports-54.txt